Reading Time: 3 minutes

HEMOVISIONAI

HemoVisionAI is our flagship R&D project soon to launch as an innovative new start-up.

It is a cloud-based, AI-powered, smartphone-integrated telehaematology platform revolutionising blood film diagnostics, especially in resource-limited settings. Designed for labs, healthcare providers, and underserved regions, it addresses the global shortage of haematologists and blood film morphologists, enabling cheaper, faster, more accurate, scalable analysis, and ensuring timely care for billions.

Who Do We Serve?

Investors: Visionaries seeking a high-growth opportunity in the booming global markets of AI-driven healthcare and telehealth.

Healthcare providers in emerging economies: Empowering access to expert haematology diagnostics and blood film analysis, bridging critical gaps in care.

SME laboratories in advanced economies: Streamlining workflows and addressing workforce shortages with affordable automation solutions.

Academic institutions: Revolutionizing haematology education and training with cutting-edge tools and AI-powered insights.

Pharmaceutical companies & research centres: Enhancing speed, accuracy, and collaboration for haematological studies without breaking the bank.

Haematology professionals: Transforming diagnostics with personal AI-powered decision support for faster, more accurate blood film analysis.

Be among the first to affordably experience the future of haematology.

JOIN THE WAITLIST!

Send an email to hemovisionai@optymumss.com with “waitlist” in the subject line.

Introduction

At Optymum SS, we are committed to delivering the best, cost-effective, innovative life science solutions for clients across all budget ranges. As part of this mission, we are developing HemoVisionAI, which will soon launch as an innovative new business line.

The Problem

Haematological disorders affect an estimated 2.5 billion people worldwide, including conditions like anaemia, leukaemia, and other blood abnormalities. The complete/full blood count (CBC/FBC) is the most requested blood test, an indispensable test, serving as the primary screening tool for these conditions, with over 10 million tests performed daily. Among these, 1-2 million require follow-up blood film examinations, a tedious and time-consuming process in which haematologists and trained morphologists analyse blood cell morphology under a microscope to identify abnormalities.

However, a global shortage of haematologists and blood film morphologists is significantly straining the diagnostic workflow. The shortage is especially dire in developing regions, with haematologist-to-patient ratios less than 1:1,000,000. Even in advanced economies, rising demand and workforce constraints create delays, inefficiencies, and diagnostic errors. In the UK, the British Society for Haematology reports that haematology is facing a shrinking workforce problem, with demand for haematological services exceeding supply. Existing solutions are few and prohibitively expensive.

Our Solution: HemoVisionAI

The platform is a smartphone-integrated, AI-powered solution that revolutionises blood film analysis and addresses critical gaps in haematology diagnostics. Our platform roll-out is in 3 phases, to ensure quick market entry and immediate impact:

Phase 1: VisionGo

Our our first offering is a semi-automated Whole Slide Imaging (WSI) platform that enables users to digitise, annotate, and share high-resolution blood film images via the cloud, as well as stream live images. VisionGo is designed for haematology research, education, and training, fostering collaboration and innovation without the need for physical slides.

Phase 2: MaaS and Telehaematology

In the second phase, HemoVisionAI introduces a Morphology-as-a-Service (MaaS) model. In tune with Industry 5.0, MaaS connects healthcare providers with a global network of expert haematologists for second opinions, complex case reviews, and case consultations. It incorporates telehaematology functionality for seamless clinical use, bridging the gap in resource-limited settings and accelerating access to specialised expertise.

Phase 3: AI-Powered Diagnostics

In the final phase HemoVisionAI evolves into an advanced AI-powered platform capable of diagnosing over 60 morphological abnormalities and haematological disorders. Using cutting-edge computer vision algorithms, the system will automate blood film analysis, providing accurate and efficient diagnostic insights, dramatically reducing workloads and improving outcomes.


Join the waiting list today!